Literature DB >> 27458283

Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?

Jessica J Lin1, Alice T Shaw2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27458283     DOI： 10.1200/JCO.2016.68.5891

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  [Histology, cytology and molecular diagnostics of lung cancer].

Authors:  T Mairinger
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

2.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.

Authors:  Jason N Rosenbaum; Ryan Bloom; Jason T Forys; Jeff Hiken; Jon R Armstrong; Julie Branson; Samantha McNulty; Priya D Velu; Kymberlie Pepin; Haley Abel; Catherine E Cottrell; John D Pfeifer; Shashikant Kulkarni; Ramaswamy Govindan; Eric Q Konnick; Christina M Lockwood; Eric J Duncavage
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

Review 3.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

4.  ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Authors:  Jeffrey S Ross; Siraj M Ali; Omotayo Fasan; Jared Block; Sumanta Pal; Julia A Elvin; Alexa B Schrock; James Suh; Sahar Nozad; Sungeun Kim; Hwa Jeong Lee; Christine E Sheehan; David M Jones; Jo-Anne Vergilio; Shakti Ramkissoon; Eric Severson; Sugganth Daniel; David Fabrizio; Garrett Frampton; Vince A Miller; Philip J Stephens; Laurie M Gay
Journal:  Oncologist       Date:  2017-10-27

5.  Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

Authors:  Wade T Iams; Christine M Lovly
Journal:  Cancer Discov       Date:  2018-07       Impact factor: 39.397

Review 6.  Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.

Authors:  Wei Wu; Franziska Haderk; Trever G Bivona
Journal:  Cancers (Basel)       Date:  2017-11-30       Impact factor: 6.639

7.  Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.

Authors:  Lei Fang; Guozheng Ding; Muzi Wang; Yuanzi Ye; Xuebo Yan; Peishan Ding; Jiong Wang; Yanbei Zhang
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.